Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Chau T. Dang

Feasibility and Cardiac Safety of Trastuzumab Emtansine After Anthracycline-Based Chemotherapy as (Neo)Adjuvant Therapy for Human Epidermal Growth Factor Receptor 2–Positive Early-Stage Breast Cancer

Journal of Clinical Oncology

English

A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-Negative HER2-Overexpressed Breast Cancer

Clinical Breast Cancer

Cancer Research

Oncology

2016

English

Related publications

Substituting Adjuvant Trastuzumab Emtansine for Herceptin Improves Survival in Patients With Human Epidermal Growth Factor Receptor 2–positive Breast Cancer

English

Safety and Efficacy of Trastuzumab Emtansine in Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: A Meta-Analysis

Scientific Reports

Multidisciplinary

2016

English

Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab With Taxane for Human Epidermal Growth Factor Receptor 2–positive Advanced Breast Cancer: Final Results From MARIANNE

English

Expression of Growth Factor Receptor Family Before and After Targeted Therapy in Human Epidermal Growth Factor Receptor-2 Positive Breast Cancer Tissues

Korean Journal of Clinical Oncology

2015

English

Ado-Trastuzumab Emtansine Targets Hepatocytes via Human Epidermal Growth Factor Receptor 2 to Induce Hepatotoxicity

Molecular Cancer Therapeutics

Cancer Research

Oncology

2015

English

FEN1 Knockdown Improves Trastuzumab Sensitivity in Human Epidermal Growth Factor 2‑positive Breast Cancer Cells

Experimental and Therapeutic Medicine

English

Trastuzumab as Adjuvant Treatment for Early Stage HER2-positive Breast Cancer — A 10 Year History

English

Trastuzumab Plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

New England Journal of Medicine

Medicine

2005

English

Cost-Utility Analysis of Adjuvant Trastuzumab Therapy for HER2-positive Early-Stage Breast Cancer in the Philippines

BMC Health Services Research

Health Policy

2019

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Chau T. Dang

Feasibility and Cardiac Safety of Trastuzumab Emtansine After Anthracycline-Based Chemotherapy as (Neo)Adjuvant Therapy for Human Epidermal Growth Factor Receptor 2–Positive Early-Stage Breast Cancer

A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-Negative HER2-Overexpressed Breast Cancer

Related publications

Substituting Adjuvant Trastuzumab Emtansine for Herceptin Improves Survival in Patients With Human Epidermal Growth Factor Receptor 2–positive Breast Cancer

Safety and Efficacy of Trastuzumab Emtansine in Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: A Meta-Analysis

Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab With Taxane for Human Epidermal Growth Factor Receptor 2–positive Advanced Breast Cancer: Final Results From MARIANNE

Expression of Growth Factor Receptor Family Before and After Targeted Therapy in Human Epidermal Growth Factor Receptor-2 Positive Breast Cancer Tissues

Ado-Trastuzumab Emtansine Targets Hepatocytes via Human Epidermal Growth Factor Receptor 2 to Induce Hepatotoxicity

FEN1 Knockdown Improves Trastuzumab Sensitivity in Human Epidermal Growth Factor 2‑positive Breast Cancer Cells

Trastuzumab as Adjuvant Treatment for Early Stage HER2-positive Breast Cancer — A 10 Year History

Trastuzumab Plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

Cost-Utility Analysis of Adjuvant Trastuzumab Therapy for HER2-positive Early-Stage Breast Cancer in the Philippines